PARP Inhibitor Biomarkers

decision foresight.png

Global PARP Inhibitor Biomarkers Market Size, Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts to 2030


The Global PARP Inhibitor Biomarkers market held USD 465.6 million in 2020 and is to grow with a CAGR of 24.2% from 2020-2030. PARP is polymerase [ADP]-ribose]. PARP is polymerase. It consists of a group of 17 enzymes combining several (poly) ADP-ribose units in a chain and transferring them into the target proteins. In the repair of single-strand DNA Poly (ADP-ribose) polymerase (PARP) inhibitor is vital. It is believed that PARP inhibitors are trapped in single-strand DNA pauses that lead to dual-strand DNA pausing when replication of the DNA is attempted. Double-stranded DNA breaks would normally be re-mediated by the HRR process, an advanced process that includes several proteins, particularly BRCA1 and BRCA2, which are also known as PARP inhibitors biomarkers.

Download Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures) @ https://www.decisionforesight.com/request-sample/DFS020403

Market Dynamics and Factors :

The main drivers for PARP inhibitors biomarkers market growth are the increasing prevalence of cancer worldwide. Cancer is a chronic disease class with out of control cell growth. According to a 2013 report published by the National Cancer Institute, more than one hundred types of cancer can be described according to their type of cells. Cancer is the world 's second leading cause of morbidity and death, according to the 2018 World Health Organization report, and it has been estimated that 9.6 million deaths occurred in 2018. In total, around 1 in 6 deaths occur because of ca, according to the same source.


Increasing breast and ovarian cancer incidences are also expected to lead to PARP inhibitors biomarkers market growth over the projected period. Breast cancer was among the 2nd largest total number of cancer cases worldwide, for example according to a 2018 report by the World Cancer Research Fund, which in 2018 accounted for 2,088,849 new cases. As per an estimated result, 266,120 new cases of invasive breast cancer were diagnosed in women in US in 2018, according to the American Cancer Society. However, high costs of PARP biomarker inhibitor test kits and tests are expected to hinder the growth of the PARP inhibitors biomarkers demand.

Market Segmentation:

  • Global PARP Inhibitor Biomarkers market – By Product Type

    • Kits

    • Assays

  • Global PARP Inhibitor Biomarkers market – By Services

    • BRCA 1 & 2 Testing

    • HRD Testing

    • HRR Testing

    • Others

  • Global PARP Inhibitor Biomarkers market – By Application

    • Breast Cancer

    • Ovarian Cancer

    • Others (Prostate, Pancreatic)

  • Global PARP Inhibitor Biomarkers market – By Geography

    • North America

      • U.S.

      • Canada

      • Mexico

    • Europe

      • U.K.

      • France

      • Germany

      • Italy

      • Rest of Europe

    • Asia-Pacific

      • Japan

      • China

      • India

      • Australia

      • Rest of Asia Pacific

    • ROW

      • Latin America

      • Middle East

      • Africa

New Business Strategies, Challenges & Policies are mentioned in Table of Content, Request TOC at @ https://www.decisionforesight.com/toc-request/DFS020403 

Geographic Analysis :

North America dominates the PARP Inhibitor biomarkers market share with the large demand owing to enhanced medical facilities in this region. In addition, in February 2019, the Australian Government announced 600 investments of 1.6 million for the Ovarian Cancer Project. The project is based on the Australian Psychosocial Support Management of Ovarian Cancer Australia, which provides care and support to Australian ovarian cancer patients through telemedicine services. According to a 2019 Australian Government report, about 400 high-risk ovarian cancer patients will benefit from the scheme. In addition, the Australian government is trying to reduce the cost of treating ovarian cancer by adding ovarian cancer treatments, such as lymphoma, into drug-benefit plans, saving approximately 90,000,000 a year.

Competitive Scenario :

Global PARP inhibitor biomarkers industry, is highly competitive, consists of a few major players. In terms of market share, few of the major players constitute large share of market. Key players enhancing the global PARP Inhibitor Biomarkers market size include Myriad Genetics, Inc., F. Hoffmann-La Roche AG, NeoGenomics Laboratories, Inc., Invitae Corporation, BPS Bioscience, Inc.

Connect to Analyst @ https://www.decisionforesight.com/speak-analyst/DFS020403 

How will this Market Intelligence Report Benefit You?

  1. The report offers statistical data in terms of value (US$) as well as Volume (units) till 2030.

  2. Exclusive insight into the key trends affecting the Global PARP Inhibitor Biomarkers industry, although key threats, opportunities and disruptive technologies that could shape the Global PARP Inhibitor Biomarkers Market supply and demand.

  3. The report tracks the leading market players that will shape and impact the Global PARP Inhibitor Biomarkers Market most.

  4. The data analysis present in the Global PARP Inhibitor Biomarkers Market report is based on the combination of both primary and secondary resources.

  5. The report helps you to understand the real effects of key market drivers or retainers on Global PARP Inhibitor Biomarkers Market business.

The 2021 Annual Global PARP Inhibitor Biomarkers Market offers:

  • 100+ charts exploring and analysing the Global PARP Inhibitor Biomarkers Market from critical angles including retail forecasts, consumer demand, production and more

  • 15+ profiles of top producing states, with highlights of market conditions and retail trends

  • Regulatory outlook, best practices, and future considerations for manufacturers and industry players seeking to meet consumer demand

  • Benchmark wholesale prices, market position, plus prices for raw materials involved in Global PARP Inhibitor Biomarkers Market type

Buy This Premium Research Report@ https://www.decisionforesight.com/checkout/DFS020403 

About Us:

Decision Foresight is a market research organization known for its reliable and genuine content, market estimation and the best analysis which is designed to deliver state-of-the-art quality syndicate reports to our customers. Apart from syndicate reports, you will find the best market insights, strategies that will help in taking better business decisions on subjects that may require you to develop and grow your business-like health, science, technology and many more. At Decision Foresight, we truly believe in disseminating the right piece of knowledge to a large section of the audience and cover the in-depth insights of market leaders across various verticals and horizontals.

Contact:

Email: sales@decisionforesight.com

For Latest Update Follow Us:

https://www.facebook.com/Decision-Foresight-110793387201935

https://twitter.com/DecisionFs

https://www.linkedin.com/company/decision-foresight/


 

Comments

Popular posts from this blog

Digital Pathology

Global Antisense And RNAi Therapeutics Market

Regenerative Therapies